Skip to main
IRON

IRON Stock Forecast & Price Target

IRON Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Disc Medicine is a promising company with a potential for significant growth in the future. Its pipeline includes several promising candidates targeting various hematologic disorders, and its financials are supported by strong collaboration and other revenue. However, there are risks associated with regulatory approval, commercialization, and financial viability, which may affect its success. The upcoming FDA meeting to discuss selcodebart as a potential treatment for myelofibrosis-associated anemia is a key development to watch for and could be a major value inflection point for the company.

Bears say

Disc Medicine is facing high clinical trial risk with the potential for failure of its pipeline candidates, including DISC-3405 and DISC-0974. The company's financials are heavily reliant on the success of its pipeline, and its valuation is not supported by current sales or projected sales in the near future. Additionally, the limited clinical data available for the company's candidates leaves room for uncertainty and further downside potential.

IRON has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Disc Medicine Inc (IRON) Forecast

Analysts have given IRON a Buy based on their latest research and market trends.

According to 9 analysts, IRON has a Buy consensus rating as of Aug 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Disc Medicine Inc (IRON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.